<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805075</url>
  </required_header>
  <id_info>
    <org_study_id>BMT303</org_study_id>
    <secondary_id>NCI-2016-00847</secondary_id>
    <secondary_id>37379</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02805075</nct_id>
  </id_info>
  <brief_title>Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>Single Arm Dose-Escalation Trial of Fructo-Oligosaccharides in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in&#xD;
      treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes&#xD;
      the transplanted cells from a donor can make an immune response against the body's normal&#xD;
      cells (called graft-versus-host disease). Nutritional supplements such as&#xD;
      fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with&#xD;
      blood cancer undergoing donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Conduct a dose escalation trial to determine the tolerability of the&#xD;
      fructo-oligosaccharides prebiotic in allogeneic hematopoeitic stem cell transplant (HSCT)&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive fructooligosaccharides (FOS) orally (PO) twice daily (BID) for 21 days&#xD;
      starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of&#xD;
      disease progression or unexpected toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 100 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 17, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose defined as the ability to take 70% of all doses over 21 days</measure>
    <time_frame>At day 21</time_frame>
    <description>Will employ the Bayesian optimal interval design.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Recurrent Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Supportive care (Fructooligosaccharide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fructooligosaccharide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (Fructooligosaccharide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Supportive care (Fructooligosaccharide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients included in the study will have a hematologic malignancy (any stage or grade)&#xD;
             for which they are undergoing preparation for allogeneic HSCT; participants in the&#xD;
             study will be restricted to those undergoing HSCT under reduced-intensity protocols&#xD;
             9924 and 9907&#xD;
&#xD;
          -  No limitations exist for type or amount of prior therapy&#xD;
&#xD;
          -  No restrictions or requirements will be placed on race&#xD;
&#xD;
          -  No restrictions will be made based on life expectancy&#xD;
&#xD;
          -  Patients will not be evaluated based on Eastern Cooperative Oncology Group (ECOG) or&#xD;
             Karnofsky performance status (KPS)&#xD;
&#xD;
          -  No restrictions will be made based on organ or marrow function&#xD;
&#xD;
          -  Patients will be included only if they have the ability to understand and the&#xD;
             willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of gastric bypass surgery or inflammatory bowel disease&#xD;
&#xD;
          -  Patients with a history of or current bowel obstruction&#xD;
&#xD;
          -  Patients actively enrolled on any other GVHD prevention trial&#xD;
&#xD;
          -  Patients with known fructose intolerance&#xD;
&#xD;
          -  Any physical or psychological condition that, in the opinion of the investigator,&#xD;
             would pose unacceptable risk to the patient or raise concern that the patient would&#xD;
             not comply with protocol procedures&#xD;
&#xD;
          -  Subjects may co-enroll on other investigational studies except for investigational&#xD;
             studies whose primary aim is the prevention of GVHD&#xD;
&#xD;
          -  No additional restrictions exist regarding co-morbid disease or incurrent illness&#xD;
&#xD;
          -  Patients will be excluded from the trial if they have had a history of allergies or&#xD;
             intolerance to fructooligosaccharides or the components of FOS including fructose and&#xD;
             glucose&#xD;
&#xD;
          -  No exclusion is necessary based on the use of other concomitant medications;&#xD;
             specifically there is no prohibition of concomitant antibiotic, antiviral or&#xD;
             antifungal therapy; subjects may co-enroll on other investigational studies except for&#xD;
             investigational studies whose primary aim is the prevention of GVHD&#xD;
&#xD;
          -  Pregnant or nursing patients will not be included in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Rezvani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tessa Andermann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrew Rezvani</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

